文献速递肿瘤 PET/CT骨显像与常规 SPECT核素与放射性配体治疗

[99mTc]Tc-PSMA-I&S-SPECT/CT:门诊中心前列腺癌显像经验

[99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center.
PubMed 文献 · EJNMMI Res · 2020-05-07

单中心对210例前列腺癌门诊患者行[99mTc]Tc-PSMA-I&S-SPECT/CT,总体PSMA阳性病灶检出率65.2%。生化复发组检出率随PSA升高而增加,PSA<1 ng/ml为20%,>4 ng/ml为82.9%,>10 ng/ml为100%。高危初诊分期组42%检出转移,晚期复发再分期组85%可检出PSMA阳性病灶。

要点

  • 210例前列腺癌患者中65.2%检出PSMA阳性病灶,主要位于淋巴结(59%)、骨(42%)和前列腺(窝)(28%)。
  • 生化复发组检出率随PSA升高而增加:PSA<1 ng/ml为20%,>4 ng/ml为82.9%,>10 ng/ml为100%。
  • 高危初诊分期组42%检出转移;晚期复发再分期组85%可检出PSMA阳性病灶。

核心结论

  • [99mTc]Tc-PSMA-I&S-SPECT/CT在前列腺癌各临床阶段均有应用价值;生化复发且PSA<4 ng/ml时检出率明显低于PET显像数据,仅当无法进行PET显像时才考虑用于病灶检测;PSA>4 ng/ml时生化复发检出率高;该检查也可用于高危初诊分期和晚期复发再分期,但这些适应证的临床价值需进一步研究。

研究设计与样本

  • 单中心对210例前列腺癌门诊患者行[99mTc]Tc-PSMA-I&S-SPECT/CT,按生化复发(152例,平均PSA 8.7 ng/ml)、高危初诊分期(12例,平均PSA 393 ng/ml)和晚期复发再分期(46例,平均PSA 101.3 ng/ml)分组分析阳性病灶数量与位置。

主要发现

  • 全部210例中65.2%检出PSMA阳性病灶,肿瘤组织主要位于淋巴结(59%)、骨(42%)和前列腺(窝)(28%);生化复发组检出率从PSA<1 ng/ml的20%升至PSA>4 ng/ml的82.9%和PSA>10 ng/ml的100%;高危初诊分期组42%显示转移;晚期复发再分期组85%的扫描可检出PSMA阳性肿瘤病灶。

关键数值与推荐

  • 生化复发组检出率按PSA分层:<1 ng/ml为20%,>4 ng/ml为82.9%,>10 ng/ml为100%;高危初诊分期组转移检出率42%;晚期复发再分期组PSMA阳性病灶可检出率85%;总体PSMA阳性病灶检出率65.2%。

临床怎么用

  • 作者认为,生化复发且PSA<4 ng/ml时该检查检出率明显低于PET显像数据,仅当无法进行PET显像时才考虑用于病灶检测;PSA>4 ng/ml时生化复发检出率高;该检查也可用于高危初诊分期和晚期复发再分期,但这些适应证的临床价值需进一步研究。

局限性

  • 原文指出,在低PSA水平(<4 ng/ml)生化复发中,[99mTc]Tc-PSMA-I&S-SPECT/CT的检出率明显低于PET显像报道的数据;作者指出这些适应证需进一步研究以评估临床价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific membrane antigen (PSMA) SPECT imaging in prostate cancer (PCa) could be a valuable alternative in regions where access to PSMA-PET imaging is restricted. [99mTc]Tc-PSMA-I&S is a new 99mTc-labeled PSMA-targeting SPECT agent, initially developed for radio-guided surgery. We report on the diagnostic use of [99mTc]Tc-PSMA-I&S-SPECT/CT in PCa. RESULTS: [99mTc]Tc-PSMA-I&S-SPECT/CT was performed and evaluated in 210 outpatients with PCa at a single center. Patients were imaged for biochemical recurrence (BCR, n = 152, mean PSA 8.7 ng/ml), for primary staging of high-risk PCa (n = 12, mean PSA 393 ng/ml), and restaging in advanced recurrent PCa (n = 46, mean PSA 101.3 ng/ml). Number and location of positive lesions were determined for the different subgroups. For BCR, detection rates were calculated, defined as the proportion of scans with at least one PSMA-positive lesion. PSMA positive lesions were detected in 65.2% of all 210 patients. Tumor tissue was mainly detected in lymph nodes (59%), in the bone (42%), and in the prostate (fossa) (28%). In the subgroup of patients referred for detection of BCR the detection rate increased from 20% at a PSA level < 1 ng/ml to 82.9% and 100% at PSA levels > 4 ng/ml and > 10 ng/ml, respectively. In the subgroup of high-risk patients referred for primary staging, 42% demonstrated metastatic disease. Restaging of advanced recurrent PCa revealed detectability of PSMA positive tumor lesions in 85% of the scans. CONCLUSIONS: [99mTc]Tc-PSMA-I&S-SPECT/CT was useful in PSMA-targeted imaging of PCa at various clinical stages. At low PSA levels (< 4 ng/ml), detection rates of [99mTc]Tc-PSMA-I&S-SPECT/CT in BCR are clearly inferior to data reported for PET-imaging and should thus only be considered for lesion detection if imaging with PET is unavailable. However, at higher PSA levels (> 4 ng/ml) [99mTc]Tc-PSMA-I&S-SPECT/CT provides high detection rates in BCR. [99mTc]Tc-PSMA-I&S-SPECT/CT can also be used for primary staging and for restaging of advanced recurrent PCa. However, further studies are needed to assess the clinical value in these indications.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Werner P, Neumann C, Eiber M, et al. [99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Res. 2020. PMID: 32382945. doi:10.1186/s13550-020-00635-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。